What's Happening?
A federal judge in Wisconsin has dismissed a lawsuit filed by Onego Bio against The EVERY Company, citing a lack of personal jurisdiction. The lawsuit, which involves a dispute over the production of ovalbumin via precision fermentation, will continue
in Delaware. Onego Bio had claimed that EVERY's demands for patent licensing fees were unwarranted and that EVERY had interfered with its business by suggesting that Onego needed a patent license. EVERY countered that Onego was the antagonist in the dispute. The judge's dismissal in Wisconsin was based on the fact that neither company is incorporated or has a business presence in the state.
Why It's Important?
This case highlights the complexities of intellectual property disputes in the rapidly growing field of alternative proteins and biomanufacturing. The outcome could have significant implications for the industry, particularly regarding patent rights and licensing agreements. A ruling in favor of EVERY could strengthen its position in the market and set a precedent for similar cases, while a decision favoring Onego could encourage other companies to challenge existing patents. The case also underscores the importance of jurisdiction in legal disputes, as companies navigate the legal landscape to protect their innovations and market positions.
What's Next?
The parallel case in Delaware will proceed, where the court will address the merits of the patent dispute. Both companies are likely to continue their legal battle, with potential implications for their business operations and investor relations. The case may also prompt other companies in the industry to reassess their patent strategies and consider the potential for litigation. As the alternative protein market continues to grow, similar disputes may arise, highlighting the need for clear legal frameworks and industry standards.
